Cargando…
Increase use of β-blockers in patients with chronic obstructive pulmonary and cardiovascular disease
Autores principales: | Yang, Yan-Li, Xiang, Zi-Jian, Yang, Jing-Hua, Wang, Wen-Jie, Xu, Zhi-Chun, Xiang, Ruo-Lan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982285/ https://www.ncbi.nlm.nih.gov/pubmed/33517398 http://dx.doi.org/10.1093/eurheartj/ehab005 |
Ejemplares similares
-
Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis
por: Yang, Yan-Li, et al.
Publicado: (2020) -
Different inflammatory pathways underlying cardiovascular risk in secondary prevention( )
por: Nurmohamed, Nick S, et al.
Publicado: (2022) -
The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl
por: Steg, Ph Gabriel, et al.
Publicado: (2021) -
A sex-specific prediction model is not enough to achieve equality for women in preventative cardiovascular medicine
por: Kimenai, Dorien M., et al.
Publicado: (2021) -
Increased absorption of phytosterols is the simplest and most plausible explanation for coronary artery disease risk not accounted for by non-HDL cholesterol in high cholesterol absorbers
por: Helgadottir, Anna, et al.
Publicado: (2020)